Parkman Healthcare Partners LLC Purchases 3,759 Shares of Waters Corporation $WAT

Parkman Healthcare Partners LLC grew its holdings in Waters Corporation (NYSE:WAT) by 14.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 30,206 shares of the medical instruments supplier’s stock after purchasing an additional 3,759 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in Waters were worth $11,328,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in WAT. Legal & General Group Plc lifted its position in shares of Waters by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 690,148 shares of the medical instruments supplier’s stock worth $258,833,000 after purchasing an additional 5,335 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Waters by 22.9% in the 2nd quarter. Jones Financial Companies Lllp now owns 290,936 shares of the medical instruments supplier’s stock valued at $108,930,000 after buying an additional 54,144 shares during the last quarter. Sone Capital Management LLC acquired a new stake in Waters in the 2nd quarter valued at approximately $22,767,000. Vega Investment Solutions increased its position in Waters by 26.7% in the 2nd quarter. Vega Investment Solutions now owns 3,749 shares of the medical instruments supplier’s stock worth $1,406,000 after buying an additional 789 shares during the period. Finally, Cibc World Market Inc. lifted its holdings in shares of Waters by 73.3% during the second quarter. Cibc World Market Inc. now owns 6,085 shares of the medical instruments supplier’s stock worth $2,282,000 after buying an additional 2,574 shares during the last quarter. 94.01% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

WAT has been the topic of several research analyst reports. HSBC raised their price objective on shares of Waters from $415.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, June 3rd. Barclays upped their target price on shares of Waters from $425.00 to $460.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Guggenheim restated a “buy” rating and issued a $440.00 price target on shares of Waters in a research report on Wednesday, July 8th. JPMorgan Chase & Co. boosted their price objective on shares of Waters from $330.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Finally, Piper Sandler initiated coverage on shares of Waters in a research report on Thursday, June 11th. They set a “neutral” rating and a $400.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $420.35.

Insider Transactions at Waters

In other news, Director Christopher A. Kuebler sold 3,626 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the transaction, the director owned 17,808 shares in the company, valued at approximately $7,086,515.52. This represents a 16.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.31% of the stock is owned by company insiders.

Waters Stock Performance

WAT opened at $410.79 on Tuesday. The stock has a market cap of $40.36 billion, a PE ratio of 102.44, a P/E/G ratio of 2.39 and a beta of 1.19. The company has a current ratio of 1.86, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32. Waters Corporation has a 1 year low of $282.77 and a 1 year high of $421.74. The stock’s 50 day simple moving average is $382.85 and its 200-day simple moving average is $347.24.

Waters (NYSE:WAT) last issued its earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, beating analysts’ consensus estimates of $3.01 by $0.04. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.62 billion. Waters had a return on equity of 11.27% and a net margin of 3.58%.Waters’s revenue was up 113.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.95 earnings per share. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Sell-side analysts forecast that Waters Corporation will post 14.57 EPS for the current year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.